✉news BusinessLabor first seen 18 h ago, last 11 h ago, peak #15
Novo Nordisk and Hengrui strike $2.6bn obesity drug deal
Original: Novo and Hengrui strike $2.6bn obesity drug deal
Danish drugmaker Novo Nordisk has agreed a deal worth $2.6 billion with China's Hengrui Pharmaceuticals, giving Novo rights to an obesity drug candidate. The agreement underscores fierce competition in the fast-growing weight-loss drug market, where Novo's Wegovy faces mounting rivalry from Eli Lilly and emerging Chinese developers.
Why now: Obesity drugs are one of the most competitive and lucrative markets in pharma right now, and a major cross-border deal involving a Chinese partner draws wide attention.
Novo NordiskHengrui PharmaceuticalsWegovy
Evidence
- Novo and Hengrui strike $2.6bn obesity drug deal · bioxconomy.com
API: https://socialmediatrends-api.osmike.com/v1/trends/606374